Analysts Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Target Price at $105.57

Posted by Brenda Bartman on Sep 20th, 2026

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has received an average recommendation of “Moderate Buy” from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $103.00.

A number of equities research analysts have recently weighed in on the company. Leerink Partners began coverage on ANI Pharmaceuticals in a report on Wednesday, September 9th. They set an “outperform” rating and a $104.00 target price for the company. Canaccord Genuity Group decreased their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Guggenheim lowered their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th.

Get Our Latest Report on ANIP

ANI Pharmaceuticals Trading Up 1.0%

Shares of NASDAQ:ANIP opened at $76.14 on Friday. ANI Pharmaceuticals has a 12-month low of $69.58 and a 12-month high of $98.04. The stock has a market cap of $1.75 billion, a PE ratio of 16.41 and a beta of 0.45. The business has a 50 day moving average of $76.18 and a 200-day moving average of $78.11. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last announced its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. The company had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The firm’s quarterly revenue was up 25.8% compared to the same quarter last year. During the same quarter last year, the company earned $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities research analysts forecast that ANI Pharmaceuticals will post 7.83 earnings per share for the current year.

Insider Activity at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $70.79, for a total value of $35,395.00. Following the completion of the sale, the vice president directly owned 73,924 shares in the company, valued at approximately $5,233,079.96. The trade was a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nikhil Lalwani sold 5,400 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $74.30, for a total value of $401,220.00. Following the sale, the chief executive officer directly owned 344,489 shares in the company, valued at $25,595,532.70. This represents a 1.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 28,325 shares of company stock valued at $2,177,695. 8.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ANIP. KBC Group NV bought a new stake in ANI Pharmaceuticals during the first quarter worth about $28,000. Hantz Financial Services Inc. increased its holdings in ANI Pharmaceuticals by 70.3% in the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after buying an additional 249 shares during the period. Persistent Asset Partners Ltd bought a new position in ANI Pharmaceuticals in the 2nd quarter valued at about $76,000. State of Wyoming acquired a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at approximately $86,000. Finally, Kingdom Financial Group LLC. bought a new stake in shares of ANI Pharmaceuticals during the 4th quarter worth approximately $141,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

(Get Free Report)

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI’s portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.